Q-omics provides the consensus-scored PLPP6 profile across patient tissues and cancer cell-line models. PLPP6 expression is associated with patient survival in 25 of 34 cancer types, with the highest sampling consensus in MESO. Among the 18 cancer types available for tumor–normal comparison, PLPP6 is differentially expressed in 10, with the highest sampling consensus in LUAD. Additionally, PLPP6 RNA expression shows 18,928 significant gene co-expression associations, with the highest sampling consensus in UVM. Together, these results highlight MESO, LUAD, and UVM as cancer lineages where PLPP6 shows reproducible signals across survival, tumor–normal expression, and patient cross-omics analyses.
Every result is evaluated using two consensus scores. Sampling consensus measures how consistently a finding is reproduced within a cancer lineage across different conditions. Lineage consensus measures how broadly the result is shared across cancer types, distinguishing pan-cancer signals from lineage-specific patterns.
Premium analyses for PLPP6 — synthetic lethality, tumor antigen, and pembrolizumab response.
This table summarizes PLPP6 survival associations across molecular data types. PLPP6 RNA expression shows survival associations in the most cancer types (25), followed by mutation status (3) and mass-spec protein abundance (4). The rightmost column indicates the cancer type with the highest sampling consensus for each molecular layer.
This table ranks reproducible PLPP6 RNA expression–survival associations across cancer types. High PLPP6 expression shows unfavorable associations in DLBC, but favorable associations in MESO, KIRC, OV, THCA and GBM. The MESO Kaplan–Meier curve shows clear separation, with the low-expression group declining faster, consistent with the favorable association (log-rank p < 0.001). Together, the overview and detailed table identify MESO as the clearest survival context for PLPP6 RNA expression.
This table summarizes PLPP6 tumor–normal expression differences by data type. RNA shows broader differences across cancer types, with a lineage consensus of 10, while mass-spec protein shows differences in 3. The strongest signals are observed in THCA for RNA and LUAD for protein.
This table ranks reproducible tumor–normal expression differences for PLPP6. A negative fold-change indicates higher expression in normal tissue than in tumor tissue. PLPP6 shows lower tumor expression in THCA, KIRC and KICH and higher tumor expression in LUAD, BLCA and BRCA. The LUAD box plot shows higher PLPP6 RNA expression in tumor versus normal tissue (log2 FC = +0.706, t-test p < 0.001).
This table shows molecular features associated with PLPP6 in patient tissues and cancer cell lines. In patient samples, PLPP6 shows the broadest associations at the RNA and protein expression levels, with UVM recurring as the lineage with the largest associated feature set. In cancer cell lines, PLPP6 RNA and mutation anchors are most strongly linked to RNA-expression features, especially in UPPER_AERODIGESTIVE_TRACT, while CRISPR and shRNA rows add functional-dependency signals in BONE and BLOOD_Lymphoma.
